These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 21398121)
1. 2-(4-Carbonylphenyl)benzoxazole inhibitors of CETP: attenuation of hERG binding and improved HDLc-raising efficacy. Sweis RF; Hunt JA; Sinclair PJ; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Cumiskey AM; Latham M; Rosa R; Peterson L; Sparrow CP; Anderson MS Bioorg Med Chem Lett; 2011 May; 21(9):2597-600. PubMed ID: 21398121 [TBL] [Abstract][Full Text] [Related]
2. 2-(4-carbonylphenyl)benzoxazole inhibitors of CETP: scaffold design and advancement in HDLc-raising efficacy. Sweis RF; Hunt JA; Kallashi F; Hammond ML; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Cumiskey AM; Latham M; Rosa R; Peterson L; Sparrow CP; Wright SD; Anderson MS; Sinclair PJ Bioorg Med Chem Lett; 2011 Mar; 21(6):1890-5. PubMed ID: 21147531 [TBL] [Abstract][Full Text] [Related]
3. 2-Arylbenzoxazoles as CETP inhibitors: raising HDL-C in cynoCETP transgenic mice. Kallashi F; Kim D; Kowalchick J; Park YJ; Hunt JA; Ali A; Smith CJ; Hammond ML; Pivnichny JV; Tong X; Xu SS; Anderson MS; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Cumiskey AM; Latham M; Peterson LB; Rosa R; Sparrow CP; Wright SD; Sinclair PJ Bioorg Med Chem Lett; 2011 Jan; 21(1):558-61. PubMed ID: 21094047 [TBL] [Abstract][Full Text] [Related]
4. 2-Arylbenzoxazoles as CETP inhibitors: Substitution of the benzoxazole moiety. Smith CJ; Ali A; Chen L; Hammond ML; Anderson MS; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Sparrow CP; Wright SD; Sinclair PJ Bioorg Med Chem Lett; 2010 Jan; 20(1):346-9. PubMed ID: 19914065 [TBL] [Abstract][Full Text] [Related]
5. 2-Arylbenzoxazoles as novel cholesteryl ester transfer protein inhibitors: optimization via array synthesis. Harikrishnan LS; Kamau MG; Herpin TF; Morton GC; Liu Y; Cooper CB; Salvati ME; Qiao JX; Wang TC; Adam LP; Taylor DS; Chen AY; Yin X; Seethala R; Peterson TL; Nirschl DS; Miller AV; Weigelt CA; Appiah KK; O'Connell JC; Michael Lawrence R Bioorg Med Chem Lett; 2008 Apr; 18(8):2640-4. PubMed ID: 18374566 [TBL] [Abstract][Full Text] [Related]
6. SAR studies on the central phenyl ring of substituted biphenyl oxazolidinone-potent CETP inhibitors. Lu Z; Chen YH; Napolitano JB; Taylor G; Ali A; Hammond ML; Deng Q; Tan E; Tong X; Xu SS; Latham MJ; Peterson LB; Anderson MS; Eveland SS; Guo Q; Hyland SA; Milot DP; Chen Y; Sparrow CP; Wright SD; Sinclair PJ Bioorg Med Chem Lett; 2012 Jan; 22(1):199-203. PubMed ID: 22142541 [TBL] [Abstract][Full Text] [Related]
7. Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib. Smith CJ; Ali A; Hammond ML; Li H; Lu Z; Napolitano J; Taylor GE; Thompson CF; Anderson MS; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Sparrow CP; Wright SD; Cumiskey AM; Latham M; Peterson LB; Rosa R; Pivnichny JV; Tong X; Xu SS; Sinclair PJ J Med Chem; 2011 Jul; 54(13):4880-95. PubMed ID: 21682257 [TBL] [Abstract][Full Text] [Related]
8. Reliable structural information for rational design of benzoxazole type potential cholesteryl ester transfer protein (CETP) inhibitors through multiple validated modeling techniques. Amin SA; Adhikari N; Gayen S; Jha T J Biomol Struct Dyn; 2019 Oct; 37(17):4528-4541. PubMed ID: 30488780 [TBL] [Abstract][Full Text] [Related]
9. Chromanol derivatives--a novel class of CETP inhibitors. Vakalopoulos A; Schmeck C; Thutewohl M; Li V; Bischoff H; Lustig K; Weber O; Paulsen H; Elias H Bioorg Med Chem Lett; 2011 Jan; 21(1):488-91. PubMed ID: 21084191 [TBL] [Abstract][Full Text] [Related]
10. Tetrazole and ester substituted tetrahydoquinoxalines as potent cholesteryl ester transfer protein inhibitors. Eary CT; Jones ZS; Groneberg RD; Burgess LE; Mareska DA; Drew MD; Blake JF; Laird ER; Balachari D; O'Sullivan M; Allen A; Marsh V Bioorg Med Chem Lett; 2007 May; 17(9):2608-13. PubMed ID: 17331716 [TBL] [Abstract][Full Text] [Related]
11. SAR study of bicyclo[4.1.0]heptanes as melanin-concentrating hormone receptor R1 antagonists: taming hERG. Su J; McKittrick BA; Tang H; Burnett DA; Clader JW; Greenlee WJ; Hawes BE; O'Neill K; Spar B; Weig B; Kowalski T; Sorota S; Li C; Liu T Bioorg Med Chem; 2007 Aug; 15(16):5369-85. PubMed ID: 17572094 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of cholesteryl ester transfer protein increases cholesteryl ester content of large HDL independently of HDL-to-HDL homotypic transfer: in vitro vs in vivo comparison using anacetrapib and dalcetrapib. Johns DG; Chen Y; Wang SP; Castro-Perez J; Previs SF; Roddy TP Eur J Pharmacol; 2015 Sep; 762():256-62. PubMed ID: 26049012 [TBL] [Abstract][Full Text] [Related]
13. 2-Arylbenzoxazoles as CETP inhibitors: substitution and modification of the alpha-alkoxyamide moiety. Hunt JA; Gonzalez S; Kallashi F; Hammond ML; Pivnichny JV; Tong X; Xu SS; Anderson MS; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Sparrow CP; Wright SD; Sinclair PJ Bioorg Med Chem Lett; 2010 Feb; 20(3):1019-22. PubMed ID: 20036121 [TBL] [Abstract][Full Text] [Related]
14. An interaction between the human cholesteryl ester transfer protein (CETP) and apolipoprotein A-I genes in transgenic mice results in a profound CETP-mediated depression of high density lipoprotein cholesterol levels. Hayek T; Chajek-Shaul T; Walsh A; Agellon LB; Moulin P; Tall AR; Breslow JL J Clin Invest; 1992 Aug; 90(2):505-10. PubMed ID: 1644921 [TBL] [Abstract][Full Text] [Related]
15. Effects of cholesteryl ester transfer protein inhibitors on human lipoprotein metabolism: why have they failed in lowering coronary heart disease risk? Schaefer EJ Curr Opin Lipidol; 2013 Jun; 24(3):259-64. PubMed ID: 23652567 [TBL] [Abstract][Full Text] [Related]
16. Potent cholesteryl ester transfer protein inhibitors of reduced lipophilicity: 1,1'-spiro-substituted hexahydrofuroquinoline derivatives. Trieselmann T; Wagner H; Fuchs K; Hamprecht D; Berta D; Cremonesi P; Streicher R; Luippold G; Volz A; Markert M; Nar H J Med Chem; 2014 Nov; 57(21):8766-76. PubMed ID: 25265559 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors. Fernandez MC; Escribano A; Mateo AI; Parthasarathy S; Martin de la Nava EM; Wang X; Cockerham SL; Beyer TP; Schmidt RJ; Cao G; Zhang Y; Jones TM; Borel A; Sweetana SA; Cannady EA; Stephenson G; Frank S; Mantlo NB Bioorg Med Chem Lett; 2012 May; 22(9):3056-62. PubMed ID: 22497761 [TBL] [Abstract][Full Text] [Related]
18. Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform. Rano TA; Sieber-McMaster E; Pelton PD; Yang M; Demarest KT; Kuo GH Bioorg Med Chem Lett; 2009 May; 19(9):2456-60. PubMed ID: 19339179 [TBL] [Abstract][Full Text] [Related]
19. Discovery of hydroxyl 1,2-diphenylethanamine analogs as potent cholesterol ester transfer protein inhibitors. Jiang J; Finlay H; Johnson JA; Harikrishnan L; Kamau M; Qiao J; Wang T; Adam L; Taylor D; Yang R; Sleph P; Chen AYA; Yin X; Wexler R; Salvati ME Bioorg Med Chem Lett; 2016 Jul; 26(14):3278-3281. PubMed ID: 27256912 [TBL] [Abstract][Full Text] [Related]
20. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. de Haan W; van der Hoogt CC; Westerterp M; Hoekstra M; Dallinga-Thie GM; Princen HM; Romijn JA; Jukema JW; Havekes LM; Rensen PC Atherosclerosis; 2008 Mar; 197(1):57-63. PubMed ID: 17868678 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]